WASHINGTON – Several memos directed toward U.S. federal prosecutors have surfaced during the current year, including one that spells out a seemingly novel policy regarding whistleblower lawsuits. A panel at a meeting of the Food and Drug Law Institute indicated that while the defense bar sees those memos as hopeful signs, the memos largely reflect the mainstream of federal prosecutor practice rather than represent a sea change in policy, leaving life sciences companies with more or less the same set of legal hazards as existed before 2018.